Annual Report

Overview

The report describes TOT BIOPHARM's 2022 strategic transformation, including commercial licensing of products, first-year sales revenue of RMB304,361 thousand and CDMO/CMO revenue of RMB72,538 thousand. It reports Board-level ESG oversight and climate-risk disclosure under TCFD, with GHG intensity of 0.26 tCO2e/RMB10'000 revenue. The company reports 431 employees, 18,003 total training hours, zero work-related deaths and 100% supplier Integrity Commitment signing.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2022
Period: 1 January 2022 – 31 December 2022
Language: English
File size
Restatement: Disclosed

Reporting standards, commitments and assurance details are available with a free account.

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP

Ratings

GRI level

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services